Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | GCGR | P47871 | 4/20 | 0.43 |
| ▸ | SLC6A9 | P48067 | 4/20 | 0.43 |
| ▸ | GCG | P01275 | 4/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.40 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 2/20 | 0.38 |
| ▸ | PPARA | Q07869 | 2/20 | 0.38 |
| ▸ | FABP2 | P12104 | 1/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6826945 | 0.95 | HPGD (0.50) | SLC6A4GCGRSLC6A9GCGHPGD | |
| SCHEMBL7208559 | 0.95 | SLC6A9 (0.51) | SLC6A4GCGRSLC6A9GCGPPARG | |
| SCHEMBL6823045 | 0.94 | SLC6A4 (0.41) | SLC6A4GCGRSLC6A9GCGLTA4H | |
| SCHEMBL7213079 | 0.88 | SLC6A4 (0.46) | SLC6A4GCGRSLC6A9GCGLTA4H | |
| SCHEMBL6823188 | 0.86 | GCGR (0.38) | SLC6A4GCGRSLC6A9GCGLTA4H | |
| SCHEMBL6566281 | 0.86 | SLC6A4 (0.55) | SLC6A4SLC6A9LTA4HADRB3PPARG | |
| SCHEMBL7214342 | 0.86 | SLC6A4 (0.45) | SLC6A4GCGRSLC6A9GCG | |
| SCHEMBL6826264 | 0.84 | SLC6A4 (0.39) | SLC6A4GCGRSLC6A9GCGLTA4H | |
| SCHEMBL6826640 | 0.83 | LTA4H (0.45) | SLC6A4GCGRSLC6A9GCGLTA4H | |
| SCHEMBL7209152 | 0.82 | SLC6A4 (0.51) | SLC6A4SLC6A9LTA4HPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1294677-A1 | BENZOPHENONES AND SULFONES AS INHIBITORS OF GLYCINE UPTAKE | Pfizer Products Inc. (US) | 2003-03-26 | — | — | EP | disclosed |
| US-6506780-B2 | Benzophenones and sulfones as inhibitors of glycine uptake | PFIZER INC. | 2003-01-14 | — | — | US | disclosed |
| US-20020052401-A1 | Benzophenones and sulfones as inhibitors of glycine uptake | PFIZER INC. | 2002-05-02 | — | — | US | disclosed |
| WO-2002000602-A1 | BENZOPHENONES AND SULFONES AS INHIBITORS OF GLYCINE UPTAKE | PFIZER PRODUCTS INC. (US) | 2002-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052401-A1 | Benzophenones and sulfones as inhibitors of glycine uptake | SLC6A1, SLC6A5, SLC1A2 | SLC6A4 7/4885GCGR 326/4885SLC6A9 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.